Illum N, Taudorf K, Heilmann C, et al. 1990. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics, 21:87–90. Inanaga K, Kumashiro H, Fukyama Y, et al. 1989. Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia, 30:438–45. Jeavons PM, Clark JE, Maheshwari MC. 1977. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate (“Epilim”). Dev Med Child Neurol, 19:9–25. Jensen PK. Felbamate in the treatment of Lennox-Gastaut syndrome. 1994. Epilepsia, 35(S5):S54–S7. Jensen FE. 2006. Pediatric epilepsy model. Epilepsy Res, 68:28–31. Johannessen CU, Johannessen SI. 2003. Valproate: past, present, and future. CNS Drug Rev, 9:199–216. Kaminski RM, Matagne A, Leclercq K, et al. 2008. SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 54:715–20. Karceski S. 2001. Vagus nerve stimulation and Lennox-Gastaut syndrome: a review of the literature and data from the VNS patient registry. CNS Spectrum, 6:766–67. Klein R, Livingston S. 1950. The effect of adrenocorticotrophic hormone in epilepsy, J Pediatr, 37:733–42. Kinsman SL, Vining EP, Quaskey SA, et al. 1992. Efﬁcacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia, 33:1132–6. Kluger G, Bauer B. 2007. Role of Ruﬁnamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat, 3:3–11. Kulig K, Malawska B. 2007. Carisbamate, a new carbamate for the treatment of epilepsy. Idrugs,10:720–7. Kwan SY, Lin JH, Wong TT, et al. 2006. A comparison of seizure outcome after callosotomy in patients with Lennox-Gastaut syndrome and a positive or negative history for West syndrome. Seizure, 15:552–7. Labar D, Nikolov B, Tarver B, et al. 1998. Vagus nerve stimulation for symptomatic generalized epilepsy: a pilot study. Epilepsia, 39:201–5. Labate A, Colosimo E, Gambardella A, et al. 2006. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure, 15:214–8. Laxer K, Blum D, Abou-Khalil BW, et al. 2000. Assessment of ganaxolone’s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group, Epilepsia, 41:1187–94. Leary LD, Wang D, Nordli Jr DR, et al. 2003. Seizure characterization and electroencephalographic features in Glut-1 deﬁciency syndrome. Epilepsia, 44:701–7. Lee YM, Kang HC, Lee JS, et al. 2008. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia, 49:685–90. Lefevre F, Aronson N. 2000. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efﬁcacy. Pediatrics, 105:E46. Lennox WG. 1945. The petit mal epilepsies; their treatment with tridione. JAMA, 129:1069–74. Lennox WG, Davis JP. 1950. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics, 5:626–44. Lerman P, Nussbaum E. 1975. The use of sulthiame- in myoclonic epilepsy of childhood and adolescence. Acta Neurol Scand Suppl, 60:7–12. Levy R, Cooper P. 2003. Cochrane Database of Systematic Reviews (3):CD001903. Liske E, Forster FM. 1963. Clinical evaluation of the anticonvulsant effects of sulthiame. J New Drugs, 3:32–6. Liu S, An N, Yang H, et al. 2007. Pediatric intractable epilepsy syndromes: Reason for early surgical intervention. Brain Dev, 29:69–78. Neuropsychiatric Disease and Treatment 2008:4(6) Lennox-Gastaut treatment Livingston JH, Beaumont D, Arzimanoglou A, et al. 1989. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol, 27:109s–112s. Lockman LA, Rothner AD, Erenberg G, et al. 1980. Cinromide in the treatment of seizures in the Lennox-Gastaut syndrome. Epilepsia, 22:241(Abstract). Lombroso CT, Davidson DTJ, Gross-Bianchi ML. 1956. Further evaluation of acetazolamide (Diamox) in treatment of epilepsy. JAMA, 160:268–72. Lombroso CT, Forsythe I. 1960. A long-term follow-up of acetazolamide (Diamox) in the treatment of epilepsy. Epilepsia, 1:493–500. Luna D, Dulac O, Pajot N, et al. 1989. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia, 30:430–7. Lundgren J, Amark P, Blennow G, et al. 1998. Vagus nerve stimulation in 16 children with refractory epilepsy. Epilepsia, 39:809–13. Machara T, Shimizu H, Oda M, et al. 1996. Surgical treatment of children with medical intractable epilepsy: outcome of various surgical procedures. Neurol Med Chi, 36:205–309. Majoie HJ, Berfelo MW, Aldenkamp AP, et al. 2001. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol, 18:419–28. Małek R, Borowicz KK, Kimber-Trojnar Z, et al. 2003. Remacemide – a novel potential antiepileptic drug. Pol J Pharmacol, 55:691–8. Manthey D, Asimiadou S, Stefovska V, et al. 2005. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol, 193:497–503. Marrosu F, Marrosu G, Rachele MG, et al. 1990. Allopurinol add-on treatment in intractable seizures. Acta Neurol (Napoli), 12:207–13. Mikaeloff Y, de Saint-Martin A, Mancini J, et al. 2003. Topiramate: efﬁcacy and tolerability in children according to epilepsy syndromes. Epilepsy Res, 53:225–32. Modur PN, Milteer WE. 2008. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav, 13:397–401. Monaghan EP, Navalta LA, Shum L, et al. 1997. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia, 38:1026–31. Morrell F, Whisler WW, Bleck TP. 1989. Multiple subpial transection: a new approach to the surgical treatment of focal epilepsy. J Neurosurg, 70:231–9. Motte J, Trevathan E, Arvidsson JF, et al. 1997. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med, 337:1807–12. Muller K, Lenard HG. 1988. The Lennox-Gastaut syndrome: therapeutic aspects including dietary measures and general management. In: Niedermeyer E, Degen D, eds. The Lennox- Gastaut syndrome. New York: Alan R. Liss, Publisher, p. 341–55. Munn R, Farrell K. 1993. Open study of clobazam in refractory epilepsy. Pediatr Neurol, 9:465–9. Naidu S, Gruener G, Brazis P. 1986. Excellent results with clorazepate in recalcitrant childhood epilepsies. Pediatr Neurol, 2:18–22. Ng YT, Collins SD. 2007. Clobazam. Neurotherapeutics, 4:138–44. Niedermeyer E. 1969. The Lennox-Gastaut syndrome, a severe type of childhood epilepsy. Dtsch Z Nervenheilk, 195:263–82. Noe F, Nissinen J, Pitkänen A, et al. 2007. Gene therapy in epilepsy: The focus on NPY. Peptides, 28:377–83. Nordgren RE, Reeves AG, Viguera AC et al. 1991. Corpus callosotomy for intractable seizures in the pediatric age group. Arch Neurol, 48:364–72. Orange JS, Hossny EM, Weiler CR, et al. 2006. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeﬁciency Committee of the American Academy of Allergy, Asthma and Immunology .Journal of Allergy and Clinical Immunology, 117(4 S1):S525–S553. 1017